– USA, MA – AffyImmune Therapeutics, Inc., a clinical-stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, today announced the appointment of Robert Forrester to its Board of Directors, bringing decades of corporate leadership experience and an established track record of scaling startups from early stage to their growth phase.
About Robert Forrester
His biotech experience spans more than two decades as CFO, COO, CEO, and board member.
“AffyImmune’s technology and team make it uniquely positioned to be an industry leader, bringing the promise of CAR T cell therapy to patients with solid tumors,” said Mr. Forrester. “It is an honor to join this team and this board as we bring hope to patients facing dire diagnoses with limited treatment options. In my previous work with ORI-incubated companies, I have seen firsthand their dedication to excellence, and that is reflected in the expert management team now assembled to lead AffyImmune into the next phase of their clinical and corporate development. I look forward to drawing on my experience and network to assist the AffyImmune team through this next phase, provide input to and help guide key strategic decisions, and provide counsel to management.”
Mr. Forrester is a co-founder of EQRx. He is also a co-founder and serves on the board of IDRx, Brixton Biosciences, and EyeCool Therapeutics. He also serves on the boards of Pillar Biosciences and Deciduous Therapeutics. He holds law degrees from the University of Bristol and the University of Law Guildford in the United Kingdom.
About AffyImmune Therapeutics, Inc.
AffyImmune is realizing the potential of cancer immunotherapy by extending the anti-cancer activity of CAR T cell therapy to solid tumors. AffyImmune’s Tune & Track platform finely tunes the affinity of CAR T cells to reduce toxicity and increase CAR T cell longevity while allowing in vivo monitoring through a proprietary tracking system. The company was founded in 2016 and in 2020 began enrolling patients in its Phase 1 trial to treat advanced thyroid cancer.
For more information: https://affyimmune.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.